Disease modification in OA — will we ever get there?
Research output: Contribution to journal › Debate/Note/Editorial
No drugs are currently approved that change the natural course of osteoarthritis (OA) and translate to long-term, clinically relevant benefits. Two-stage clinical trial designs for OA have now received FDA approval, but remaining challenges lie in defining suitable study populations, surrogate outcomes and pivotal long-term, clinically relevant trial endpoints.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY